ArticleFrontiers in toxicology2026
A case report of arsenic-induced peripheral neuropathy misdiagnosed as Guillain-Barré syndrome.
Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the clinical characteristics and misdiagnosis causes of arsenic-induced peripheral neuropathy. Methods: We report a case of arsenic-induced peripheral neuropathy initially misdiagnosed as Guillain-Barré syndrome, with analysis of clinical characteristics, diagnostic workup and therapeutic management, supplemented by literature review. Results: A 58-year-old male presented with progressive peripheral neuropathy, initially diagnosed with Guillain-Barré syndrome but later suspected as chronic inflammatory demyelinating polyneuropathy. However, his symptoms progressed despite standard immunotherapy, developing generalized motor deficits, myokymia, ascending sensory loss, and facial palsy. Careful reevaluation revealed critical diagnostic clues: a history of intermittent topical application of an unidentified herbal medicine preceding symptom onset, accompanying gastrointestinal prodromal symptoms, and characteristic physical findings including Mee's lines, lower limb hyperpigmentation, and foot hyperkeratosis. Subsequent laboratory testing confirmed markedly elevated arsenic levels in nail and hair samples, ultimately establishing the diagnosis of arsenic-induced peripheral neuropathy. Conclusion: Arsenic-induced peripheral neuropathy can clinically mimic Guillain-Barré syndrome. For immunotherapy-refractory cases, clinicians should maintain high suspicion for potential heavy metal poisoning. Careful elicitation of toxic exposure history and recognition of characteristic dermatologic findings are critical for definitive diagnosis, as early recognition significantly improves prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.